The Effects of ProFoveate on Reducing Self-Stimulating Behaviors: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for The Effects of ProFoveate on Reducing Self-Stimulating Behaviors (NCT02088047), a randomized na study. The primary outcome is Numbers of Self-stimulating Behaviors.

2. Clinical Question

This is a pilot question about a behavioral outcome and the feasibility of collecting measurements in the intended population. The registry record describes the investigators’ hypothesis that strategic placement of ProFoveate pellets would be associated with changes in self-stimulating behaviors. A hypothesis is not evidence that a change occurred. The small number of participants who completed the study and the absence of a reported comparative analysis mean that the posted results cannot establish whether the outcome differed between the groups.

3. Trial Design

The record describes a randomized, parallel-group study with no masking. Participants were assigned to a ProFoveate group or a no-intervention control group. The intervention involved steel pellets placed on the ears according to instructions, while the control group received no intervention. Both groups were assessed at baseline and again after 4 weeks. The registry record lists the study as terminated and gives low enrollment as the reason for termination.

The intended assessment included the Social Skills Improvement System, parent report, and observational data. The primary outcome is described as the number of self-stimulating behaviors over the baseline-to-4-weeks timeframe. The record does not specify how the observations were combined into the reported outcome, who conducted the observations, or whether assessors were independent of the intervention.

The registry lists enrollment of 4. Its outcome description states that only 4 participants completed enrollment and only 3 completed the study. The arm-level results list 3 participants in the ProFoveate group and 1 in the NonProFoveate group. These counts show how limited the observed dataset was, but the record does not explain the study’s participant flow in detail or identify why a participant did not complete the study.

Randomization can help balance participant characteristics across groups in a sufficiently informative study, but it does not guarantee balance in a very small sample. With no masking and a behavioral outcome assessed through observation and parent report, awareness of group assignment could also be relevant to how measurements were made or interpreted. Whether these issues affected the results cannot be determined from the registry record. The allocation method, masking of outcome assessors, and detailed operational procedures are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Students were given a Social Skills Improvement System (SSiS). Only 4 participants completed enrollment. Only 3 participants completed study. Study was terminated due to low enrollment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Numbers of Self-stimulating Behaviors, measured over Baseline to 4 Weeks.

The primary endpoint is titled “Numbers of Self-stimulating Behaviors.” It is a continuous measure summarized as a mean and standard deviation, with the unit described as behaviors. The study summary identifies examples of self-stimulating behaviors, including hand flapping, eye blinking, and rocking, and notes that the investigators aimed to document behavior through parent report and observational data.

Tracking a behavioral outcome can describe how often targeted behaviors are observed and whether their measured frequency changes over time. The registry record frames the assessment period as baseline to 4 Weeks and describes assessments at the beginning and end of the study. However, it does not define the scoring procedure, observation duration, aggregation method, or whether the posted arm values refer to baseline, end-line, or change scores. That ambiguity limits what can be inferred from the means.

In general, a continuous endpoint preserves more information than a simple classification because participants can have different measured values across a range. A mean describes the group’s average value, while the standard deviation describes dispersion of individual values around that mean. Neither statistic alone establishes that an intervention caused a change. Interpretation also depends on a clearly defined outcome, comparable measurements over time, and a suitable analysis of the randomized groups. Those details are not fully reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a mean describe? A mean is the arithmetic average of the observed values in a group. For this continuous endpoint, the registry reports means in behaviors for the Profoveate and NonProFoveate arms. The mean can be a useful compact description, but it does not reveal whether individual observations were clustered near the average or varied widely. It also does not show how measurements changed over time unless the underlying quantity is explicitly defined as a change score.

What does a standard deviation describe? The standard deviation summarizes the spread of observations around the mean. A larger standard deviation indicates more dispersion in the measured values within the group; a smaller one indicates less observed dispersion. General statistical interpretation depends on the amount and quality of data behind the summary. In the NonProFoveate arm, only one participant is listed, so the reported standard deviation of 1.6 cannot characterize variation among participants. The registry gives a standard deviation of 7.24 for the Profoveate arm, but the very limited group size makes that estimate an unstable basis for describing the broader population.

Why is the endpoint definition important? The registry identifies a baseline-to-4-weeks timeframe and says that participants were assessed at the beginning and end of the study. However, it does not state whether the posted means summarize measurements at baseline, at the end, or the difference between the two. These are distinct quantities. A baseline mean describes the groups before the intervention period; an end-line mean describes the groups at its close; a change score describes within-participant movement across the period. Without knowing which quantity is reported, the means cannot be interpreted as evidence of change or as a direct group contrast.

What does randomization contribute? In general, random assignment is intended to make the groups comparable on average, including on measured and unmeasured characteristics. It does not guarantee that groups will be similar in every small study, particularly when few participants are enrolled. The record labels the study randomized, but the sequence-generation and allocation-concealment procedures are not reported in the registry record. The record also lists no masking. In a behavioral study involving parent report and observational data, knowledge of assignment can be relevant to outcome assessment. The extent of any such influence is not reported.

What would a comparative analysis address? A comparative analysis would estimate how the outcome differs between randomized groups, using a clearly defined measurement and a stated statistical approach. An uncertainty interval, such as a confidence interval, gives a range of values compatible with the data and model assumptions. In general, a narrow interval indicates greater precision and a wide interval indicates less precision. The registry record reports no arm-comparison analysis, confidence interval, or p-value. The available descriptive summaries therefore do not provide an inferential estimate of the difference between groups.

For a continuous outcome, the choice of analysis can depend on the endpoint definition, repeated measurements, distribution of values, and handling of missing observations. A model for measurements at baseline and end-line may answer a different question from a comparison of change scores or a comparison of end-line means. General statistical methods cannot resolve ambiguity in the underlying outcome definition. The registry record does not report a statistical analysis plan, a model, covariate adjustments, or a method for using repeated measurements.

General concepts such as over-dispersion matter when the analysis model assumes a particular degree of variability. Over-dispersion means that observed variability exceeds what a model expects; if present and ignored, uncertainty estimates can be misleading. It is not possible to assess over-dispersion from the posted arm summaries, and the registry does not identify a count-data model. More fundamentally, the record describes the endpoint as continuous and reports a mean and standard deviation, without explaining the distribution or scoring scale used to create those values.

Planning calculations based on an observed effect are not observed power. In general, power calculations illustrate the sample size that would be needed under stated assumptions about the effect, allocation, significance level, and statistical model. The registry record describes a planning approach based on a fraction of an observed effect, with a two-sided significance level of 0.05, equal allocation, and a normal approximation. Any such calculation is a planning illustration rather than a measure of the probability that this completed study detected an effect. The record does not report the trial’s own sample-size justification or statistical plan, and no planning results are stated in the registry record.

Randomization, descriptive summaries, and a planning calculation each serve different purposes. Randomization defines how participants are assigned; summary statistics describe observed data; and planning calculations concern hypothetical future study design. None replaces a clearly specified endpoint and a comparative analysis. For this record, the absence of a reported comparison and the ambiguity about what the arm means represent are central limitations to statistical interpretation.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Profoveate", "NonProFoveate")
n   <- c(3, 1)
m   <- c(40, 27)
sp  <- c(7.24, 1.6)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Profoveate  3  40.000  7.240  22.015  57.985
CARM  NonProFoveate  1  27.000  1.600  NaN  NaN

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists 1 outcome measure and 0 posted secondary outcomes. It reports 0 analyses. Since no comparative analysis is reported, there is no stated collection of hypothesis tests for which a multiplicity adjustment can be assessed. Whether any additional outcomes or analyses were considered during the study is not reported in the registry record. The record also does not report a prespecified statistical analysis plan, so it is not possible to assess whether analyses or outcome choices followed a prior plan.

The outcome description says that only 4 participants completed enrollment and only 3 completed the study. The arm-level summaries list 3 participants in the Profoveate group and 1 in the NonProFoveate group. The reason a participant did not complete the study, the amount of missing outcome information, and the timing of any missingness are not reported in the registry record. The stated reason for termination is low enrollment, but that does not specify the missing-data process for individual outcomes.

In general, missing data can affect estimates when the probability of an observation being missing is related to participant characteristics or outcomes. Methods for handling missingness depend on why data are missing and on the analysis objective. No missing-data method, imputation procedure, or sensitivity analysis is reported. The analysis population definitions—such as whether participants were analyzed according to randomized assignment—are also not reported in the registry record. With the limited completion information and no reported analysis, the effect of missing data cannot be evaluated.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 00% reporting threshold.

The posted safety figures list serious adverse events for the Profoveate group as 0 affected among 2 at risk, and for the NonProFoveate group as 0 affected among 1 at risk. Deaths are listed as 0 in both groups. For other adverse events, the record likewise lists 0 affected among 2 at risk in the Profoveate group and 0 affected among 1 at risk in the NonProFoveate group. No serious adverse event terms are listed.

These are the counts recorded in the registry, not proof that an intervention has no safety risks. The number of participants represented is very limited, and the record’s at-risk counts differ from the arm sizes listed for the primary outcome. The registry record does not explain that difference or describe the methods used to collect and classify adverse events. With so few participants, absence of a recorded event cannot establish that an event would not occur in a larger or different population. The safety figures should be read as a limited account of events recorded during this study, rather than as a precise estimate of risk.

13. What the Result Does, and Does Not, Mean

The results establish that the registry contains descriptive arm summaries for the primary behavioral outcome and records a study that ended after low enrollment. They show reported means and standard deviations for the two randomized groups, along with participant counts for those summaries. They also show that the registry lists no affected participants for serious or other adverse events among the recorded at-risk groups. These are statements about what the record reports, not conclusions about the intervention’s effect.

The posted results do not establish that ProFoveate reduced self-stimulating behaviors, increased them, or had no effect. The record does not make clear whether the outcome summaries are baseline measurements, end-line measurements, or changes. It also reports no statistical comparison, uncertainty interval, or p-value. Without an interpretable comparison, the arm-level means cannot answer whether the groups differed over the study period.

Nor can the results establish how the intervention would perform in a broader population. Few participants completed the study, the control-group summary is based on one participant, and the record does not provide enough detail to assess how representative the enrolled participants were. The study’s termination because of low enrollment further limits the information available.

In general, a pilot study can offer preliminary information about conducting an intervention and collecting outcome data. Its descriptive results may help identify questions that require clearer outcome definitions, adequate enrollment, and a prespecified analysis in later research. Such general considerations do not convert these results into evidence of efficacy or establish a safety profile. The registry record supports a narrow conclusion: it reports small-sample descriptive results, but does not report a comparative finding that resolves the study’s stated question.

14. Why This Trial Matters Statistically

This study is statistically informative in part because it illustrates how limited enrollment constrains interpretation. Randomization is useful for comparative research, but random assignment alone does not make a small set of observations precise. Here, the outcome summaries are based on very few participants, and the control arm has only one participant listed. The resulting means and standard deviations cannot provide a dependable picture of variability across the target population.

The record also highlights the importance of defining an endpoint operationally. A title and timeframe identify the broad subject of measurement, but the reader also needs to know exactly how observations were scored and whether reported values refer to baseline, end-line, or change. When that distinction is missing, even correctly reported summary statistics may not answer the intended research question.

The absence of a reported comparative analysis matters as much as the small sample. Descriptive arm summaries are not a substitute for an estimate of the difference between randomized groups and its uncertainty. A clear analysis plan, explicit outcome definition, and transparent participant flow would help readers assess what a study can say, even when enrollment is limited. This record therefore offers a useful statistical caution: the presence of randomization and numerical results does not by itself establish an interpretable treatment effect.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this study restrict interpretation. The registry reports enrollment of 4, states that only 3 participants completed the study, and lists arm-level outcome summaries based on 3 participants in the Profoveate group and 1 in the NonProFoveate group. The study was terminated because of low enrollment. These registry entries leave little information for estimating group averages or variability, particularly in the control arm.

The outcome is described as the number of self-stimulating behaviors over baseline to 4 Weeks, but the record does not identify whether the posted arm values are baseline, end-line, or change measurements. It also does not give the scoring rules, observation period, or detail on how parent reports and observational data contributed to the endpoint. This prevents a clear interpretation of the means as changes over time.

No statistical comparison is reported, and the record does not give confidence intervals, p-values, a missing-data method, an analysis population definition, or a statistical analysis plan. Randomization is listed, but its implementation is not described; masking is listed as none, and assessor masking is not reported. The adverse-event at-risk counts are smaller than the primary outcome arm counts, with no explanation in the registry record. Each limitation reduces the certainty and scope of what can be concluded from the posted information.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: The Effects of ProFoveate on Reducing Self-Stimulating Behaviors — NCT02088047.
• Registry record last updated 2020-10-09; status last verified 2020-09.
• Results first posted 2020-10-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT02088047 is a randomized, unmasked, parallel-group study sponsored by the University of Arkansas. It evaluated ProFoveate pellets versus no intervention for self-stimulating behaviors in children diagnosed with autism spectrum disorders. The intended assessment ran from baseline to 4 Weeks. The registry lists the study as terminated because of low enrollment.

The primary outcome is the number of self-stimulating behaviors, summarized as a mean and standard deviation. The posted arm summaries are 40.0 with a standard deviation of 7.24 for Profoveate and 27.0 with a standard deviation of 1.6 for NonProFoveate. The record does not clarify the timing represented by those values and reports no comparative analysis. Only 3 participants completed the study. The posted data are descriptive and do not establish a treatment effect.